Digbi Health, the national leader in Precision Biology–based chronic care, announced peer-reviewed, actuarially validated significant healthcare cost savings for employers. The findings of this multi-year, multi-employer medical claims analysis were published in the prestigious journal Healthcare.

The analysis confirms that employers using Digbi Health’s Precision Biology platform can achieve actuarially guaranteed, hard-dollar reductions in medical claims, driven by lower pharmaceutical utilisation and reduced inpatient and outpatient costs. These savings were achieved by treating the root cause of multiple chronic conditions — including obesity, metabolic, gastrointestinal, mental health, and autoimmune conditions — on a single platform, informed by over 8000 gut microbiome, genetic, and blood biomarkers.

This announcement marks a critical milestone for digital health, an industry that has historically relied on “soft” and “vibe” ROI metrics such as engagement while struggling to demonstrate direct reductions in medical costs.

Key Study Findings:

The claims analysis evaluated multiple years of medical spend across seven U.S. self-insured employers, comparing Digbi Health participants with matched non-participants. The study identified significant reductions in medical claims, including:

Obesity-related medical cost reduction: -$4,884 per member per year (PMPY)

Digestive and GI cost reduction: -$9,240 PMPY

Anxiety-related medical cost reduction: - $1,356 PMPY

Overall medical spend Reduction: -$3,012 PMPY

Precision Biology as the New Standard of Care

This study demonstrates that treating multiple metabolic and gastrointestinal conditions through a single platform, utilising gut microbiome biomarkers, which is now recommended by the USDA, and genetics-driven care, can result in significant savings for employers, said Ranjan Sinha, founder & CEO of Digbi Health. “Our precision biology-based approach shows that the right combination of innovative medical science, clinical expertise, and AI-supported personalised patient engagement can effectively address the chronic health crisis, improve outcomes for families, and deliver meaningful savings to employers and health plans. These results are a testament to the tireless efforts of the entire Digbi team, and I’m incredibly grateful to the over 100 employers who trust our Precision Biology-based approach, making it the new standard of care.